A5030926405- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Cancer Studies
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Brain Metastases and Treatment
- Cancer therapeutics and mechanisms
- Immune cells in cancer
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Neuroendocrine Tumor Research Advances
- Myasthenia Gravis and Thymoma
- Esophageal and GI Pathology
Samsung Medical Center
2016-2025
Sungkyunkwan University
2016-2025
Sun Yat-sen Memorial Hospital
2021
Sun Yat-sen University
2021
Samsung (South Korea)
2021
Weatherford College
2020
Zero to Three
2016
Seoul St. Mary's Hospital
2015
Yonsei University Health System
2015
Seoul National University Bundang Hospital
2008-2009
Abstract Advanced metastatic cancer poses utmost clinical challenges and may present molecular cellular features distinct from an early-stage cancer. Herein, we single-cell transcriptome profiling of lung adenocarcinoma, the most prevalent histological type diagnosed at stage IV in over 40% all cases. From 208,506 cells populating normal tissues or early to 44 patients, identify a cell subtype deviating differentiation trajectory dominating stage. In stages, stromal immune dynamics reveal...
Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety osimertinib in NSCLC harboring EGFR
Limited treatment options exist for patients with thymic epithelial tumor (TET) whose disease progresses after platinum-based chemotherapy. We conducted a phase II study of pembrolizumab in TET to evaluate its efficacy and safety.Patients histologically confirmed progressed at least one line chemotherapy were eligible the study. Patients excluded if they had an active autoimmune requiring systemic within past year or documented history clinically severe disease. received 200 mg intravenously...
To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) same agents in locally advanced non-small-cell lung cancer (LA-NSCLC).Patients were randomly assigned to either CCRT alone (observation arm) or followed by CC (consolidation arm). (20 mg/m(2)) was administered every week for 6 weeks a total dose 66 Gy thoracic radiotherapy 33 fractions. In arm, patients further treated three cycles DP (35 mg/m(2) each on...
Abstract Purpose: The evaluation of plasma testing for the EGFR resistance mutation T790M in NSCLC patients has not been broadly explored. We investigated detection activating and mutations matched tumor tissue plasma, mostly from with acquired to first-generation inhibitors. Experimental Design: Samples were obtained two studies, an observational study a phase I trial rociletinib, mutant-selective inhibitor that targets both T790M. Plasma was performed cobas test BEAMing. Results: positive...
Abstract Purpose: To investigate blood-based dynamic biomarkers that predict responses to anti–programmed cell death protein 1 (PD-1) therapy in solid tumors. Experimental Design: Preplanned biomarker analysis was performed as part of a phase II clinical trial (NCT02607631) patients with metastatic or refractory thymic epithelial tumors (TETs; n = 31) who received pembrolizumab. The further tested an independent cohort prospectively recruited non–small lung cancer (NSCLC) pembrolizumab...
Background: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines first-line treatment of EGJ recommend chemotherapy containing a platinum and fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated gastroesophageal cancer. Aim: To describe the design rationale randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate...
•Osimertinib 160 mg exhibited promising ORR and survival benefit in EGFR T790M-positive NSCLC patients with CNS metastasis.•As it caused only grade 1–2 adverse events, osimertinib also showed a tolerable safety profile.•It is suitable for BM or LM after TKI treatment those treated T790M-targeting agents radiotherapy. BackgroundUp to 40% of non-small-cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutations tyrosine kinase inhibitors (TKIs) present disease progression the...
245 Background: Inhibition of TIGIT, a novel checkpoint inhibitor, may further amplify immune responses by complementing the PD-L1/PD-1 pathway. Anti-tumor activity has been demonstrated with cancer immunotherapy in ESCC. SKYSCRAPER-08 (NCT04540211) is evaluating efficacy and safety tira (anti-TIGIT) + atezo (anti-PD-L1) combination CT compared placebo as 1L treatment (tx) an Asian population unresectable locally advanced (LA), recurrent, or metastatic (R/M) Methods: Eligible pts (confirmed...
Recent studies have reported the predictive and prognostic value of novel transcriptional factor-based molecular subtypes in small-cell lung cancer (SCLC). We conducted an in-depth analysis pairing multi-omics data with immunohistochemistry (IHC) to elucidate underlying characteristics associated differences clinical outcomes between subtypes.
Purpose Lung squamous cell carcinoma (SCC) is the second most prevalent type of lung cancer. Currently, no targeted therapeutics are approved for treatment this cancer, largely because a lack systematic understanding molecular pathogenesis disease. To identify therapeutic targets and perform comparative analyses SCC, we probed somatic genome alterations SCC by using samples from Korean patients. Patients Methods We performed whole-exome sequencing DNA 104 patients matched normal DNA. In...
Oropharyngeal squamous cell carcinoma (OSCC) has been recognized as an immunosuppressive disease. Various mechanisms have proposed for immune escape, including dysregulation of checkpoints such the PD-1:PD-L1 pathway. We investigated expression programmed death-ligand 1 (PD-L1) in HPV-negative and HPV-positive OSCC to determine its prevalence prognostic relevance.Using immunohistochemistry, 133 cases were evaluated PD-L1. Formalin-fixed paraffin-embedded tumor samples stained with monoclonal...
Immune checkpoint inhibitors (ICIs) have been shown to be beneficial for some patients with advanced non-small-cell lung cancer (NSCLC). However, the underlying mechanisms mediating limited response ICIs remain unclear.We carried out whole-exome sequencing on 198 NSCLC tumors that had sampled before anti-programmed cell death 1 (anti-PD-1)/programmed death-ligand (PD-L1) therapy. Detailed clinical characteristics were collected these patients. We designed a new method estimate human...
This study is to evaluate whether thymidylate synthase (TS) or thyroid transcription factor 1 (TTF1) protein expression can predict clinical outcomes for pemetrexed-based chemotherapy in patients with nonsquamous non-small cell lung cancer (NSCLC).Two hundred eighty-five consecutive NSCLC treated were immunohistochemically analyzed the expressions of TS and TTF1.TS TTF1 successfully 193 284 cases, respectively. Tumors TS-negativity TTF1-positivity more frequent who female, younger, had...